Novartis took its first big hit from new Diovan generics during last year's third quarter, when Ranbaxy Laboratories finally won approval for its exclusive generic of the blood pressure pill. And it was indeed a big hit: a 76% drop in U.S. sales for ... FiercePharma, 2 months ago
Summary GBI Research, the leading business intelligence provider, has released its latest research, Antihypertensive Therapeutics in Major Developed Markets to 2020 Increased Uptake of Combination Therapies to Offset Effects of Key Patent ...Creative Times, 2 weeks ago Market Overview - Antihypertensive Therapeutics in Major Developed Industry 2020: Radiant Insights, Inc Press Release Ping, 2 weeks ago Cardiovascular Drugs Market - Global Industry Size, Share, Trends Analysis to 2020 Digital Journal, 2 weeks ago Antihypertensive Therapeutics in Major Developed Market Size, Share, Trends Analysis... Creative Times, 2 weeks ago
Research and Markets (http://www.researchandmarkets.com/research/vzs98b/valsartan) has announced the addition of the "Valsartan - Comprehensive patent search" report to their offering. Imagine having your own team of pharmaceutical patent experts at ...Individual.com, 1 month ago Research and Markets: Valsartan - 2015 Comprehensive Patent Search TeleTrader.com, 4 weeks ago
The present invention relates to a method for forming a pharmaceutical product, such as a dissolvable film dosage form, onto a surface. Particularly, the present invention relates to a method of forming a pharmaceutical product directly onto the ...PharmCast, 1 month ago
Novartis A.G . ( NVS ) reported fourth-quarter 2014 earnings of 62 cents per share, down 23% from the year-ago period. Core earnings per share came in at $1.21, up from $1.18 in the year-ago period and beat the Zacks Consensus Estimate of $1.13.Zacks.com, 1 month ago
Novartis a enregistré en 2014 une forte augmentation de ses ventes, sa marge et progrès de son pipeline; la transformation du portefeuille concentrera l'entreprise sur ses principales activités - HTML (w)
Company : NOVARTIS Compartment : Other ISIN : CH0012005267 Wire : Thomson Reuters ONE Document type : Permanent Information Releases / General Company News Publication date : 1/27/2015 7:00:00 AM ...WorldRegInfo, 2 months ago Novartis : delivered solid sales growth, margin expansion and pipeline progress in 2014; portfolio transformation will focus company on leading businesses 4 Traders, 2 months ago Novartis delivered solid sales growth, margin expansion and pipeline progress in 2014; portfolio transformation will focus company on leading businesses Sante Log, 2 months ago REG-Novartis delivered solid sales growth, margin expansion and pipeline progress in 2014; portfolio transformation will focus company on leading businesses Reuters, 2 months ago
on your WebpageAdd Widget >Get your members hooked!